
Daiichi Sankyo believes that the claims made in this litigation are without merit, and does not admit liability.”
We don’t believe we did anything wrong and it doesn’t matter much anyway ...
continue reading...
Daiichi Sankyo believes that the claims made in this litigation are without merit, and does not admit liability.”
We don’t believe we did anything wrong and it doesn’t matter much anyway ...
continue reading...Given the upcoming deadline, Lopez McHugh, LLP will discontinue evaluations of Benicar lawsuits after August 19, 2017.


Over 1,100 Benicar lawsuits are pending in a New Jersey multidistrict litigation, according to recent court estimates. Plaintiffs who have filed Benicar lawsuits claim that Japanese ...
continue reading...
Diverticulitis, a digestive disease wherein small pouches in the intestines or colon become inflamed, can lead to severe pain, fever, nausea, and diarrhea. It is just one of several serious gastrointestinal problems that have been associated with Benicar. In 2013, the U.S. Food and Drug Administration (FDA) released ...
continue reading...
Benicar, Daiichi Sankyo’s brand-name olmesartan, was approved in 2002 by the U.S. Food and Drug ...
continue reading...
Benicar is Japan-based company Daiichi Sankyo’s bestselling hypertension drug. The U.S. Food and Drug Administration (FDA) approved Benicar in 2002, and since then the drug has been prescribed to over 11 million U.S. patients. But in 2013, the ...
continue reading...